Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have reached a global settlement, resolving all litigation related to navepegritide products. Ascendis gains worldwide rights to develop and commercialize these products in exchange for royalty payments to BioMarin on YUVIWEL sales through 2030, which is a significant development for Ascendis's product pipeline and revenue projections.
Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding global settlement and license agreement. This resolves all ongoing litigation between the two companies regarding navepegritide-related products, including YUVIWEL. For Ascendis, this is a significant positive as it secures unrestricted worldwide rights to develop and commercialize these products, which are key to its future revenue projections of €5 billion by 2030. BioMarin will receive royalty payments on net sales of YUVIWEL in specific regions through May 2030, providing a revenue stream without further litigation costs. This agreement removes a significant legal overhang for Ascendis, potentially boosting investor confidence and allowing the company to focus on product development and commercialization. For BioMarin, it monetizes intellectual property without the burden of further legal battles. The short-term impact for ASND is likely positive due to reduced uncertainty, while the long-term implications involve the successful execution of their commercialization strategy for navepegritide products.